HLB bioStep Non-Registered Director Han Sang-ok Increases Stake to 0.04% via Open Market Purchase, Limited Impact on Shareholder Value

HLB bioStep non-registered director Han Sang-ok acquired an additional 2,165 common shares through open market purchases on three occasions from June 5 to June 10, 2026.
This purchase increases Han's total holdings from 4,980 to 7,145 shares, representing 0.04% of total outstanding shares.
The transaction is a small personal investment using private funds, causing no change to the company's capital structure or share count, thus no dilution risk.
While the insider's voluntary purchase may indirectly signal management confidence, the negligible stake means limited practical impact on stock price.
[AI Summary]This filing reports a minor insider open-market purchase unrelated to corporate capital actions or financial strategy. It provides no special market signal and has a neutral impact on shareholder value.